Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 7/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21389489 | 0.91 | GDA (0.59) | GDAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9194843 | 0.87 | GDA (0.62) | GDAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11380140 | 0.85 | GDA (0.56) | GDAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10181080 | 0.84 | ADORA2A (0.54) | GDAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25286007 | 0.84 | GDA (0.55) | GDAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7453665 | 0.83 | GDA (0.58) | GDAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10408059 | 0.81 | GDA (0.55) | GDAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10408058 | 0.81 | GDA (0.55) | GDAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18175084 | 0.80 | GDA (0.54) | GDAPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7454607 | 0.80 | GDA (0.54) | GDAPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025046257-A1 | A SUBSTANTIALLY PURE PROPENTOFYLLINE AND PREPARATION THEREOF | HIKAL LIMITED (IN) | 2025-03-06 | — | — | WO | claimed |
| US-6710051-B1 | SUBSTANCES IS A XANTHINE AND IS ADMINISTERED IN A DOSAGE OF 7.5-750 MG 1-4 TIMES DAILY TO TREAT MYOPIA | KLAUS TRIER APS (DK) | 2004-03-23 | — | — | US | claimed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | claimed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | claimed |
| EP-0252043-A1 | Method for the preparation of 3-n-propyl-xanthine | Aktiebolaget Draco (SE) | 1988-01-07 | — | — | EP | claimed |
| CN-110573509-B | MLKL inhibitors | 北京生命科学研究所 | 2023-05-26 | — | — | CN | disclosed |
| EP-2473053-A1 | SUBSTITUTED XANTHINE DERIVATIVES | Concert Pharmaceuticals Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| EP-2473052-A1 | SUBSTITUTED XANTHINE DERIVATIVES | Concert Pharmaceuticals Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011028922-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011028835-A1 | SUBSTITUTED XANTHINE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-03-10 | — | — | WO | disclosed |
| WO-2008033754-A2 | XANTHINE DERIVATIVES IN METHODS AND COMPOSITIONS FOR THE TREATMENT OF VASCULAR DEPRESSION | DUKE UNIVERSITY (US) | 2008-03-20 | — | — | WO | disclosed |
| US-6710051-B1 | SUBSTANCES IS A XANTHINE AND IS ADMINISTERED IN A DOSAGE OF 7.5-750 MG 1-4 TIMES DAILY TO TREAT MYOPIA | KLAUS TRIER APS (DK) | 2004-03-23 | — | — | US | disclosed |
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | TRIER KLAUS (DK) | 2004-01-22 | — | — | US | disclosed |
| WO-1998030900-A2 | SCREENING METHOD FOR COMPOUNDS ACTIVE IN TREATING MYOPIA AND HYPERMETROPIA | KLAUS TRIER APS (DK) | 1998-07-16 | — | — | WO | disclosed |
| US-5055457-A | Antiviral; sulfated polysaccharide and xanthine derivative | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-10-08 | — | — | US | disclosed |
| EP-0252043-A1 | Method for the preparation of 3-n-propyl-xanthine | Aktiebolaget Draco (SE) | 1988-01-07 | — | — | EP | disclosed |
| EP-0252043-A1 | Method for the preparation of 3-n-propyl-xanthine | Aktiebolaget Draco (SE) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040013609-A1 | For identification of substances for treatment or prevention of insufficient longitudinal growth of eye(hypermetropia) or excessive longitudinal growth of eye(myopia); involves measurement of effect on retinal pigment epithelium | RYR1, ATP2A2, ATP2A1 | GDA 2944/4885PDE4A 818/4885PDE4B 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.